Rankings/Komodo Health
Komodo Health logo

Komodo Health

IntegratedAI NativePrivateUpdated November 15, 2026

330 million patient journeys turned into the pharmaceutical industry's most powerful AI analytics engine.

Founded
2014
CEO
Arif Nathoo and Web Sun (co-CEOs)
HQ
San Francisco, CA, United States
Stage
Series F
Revenue
Not disclosed
Total Funding
$587M
Employees
201-500
Flag a data issue
Healthcare ToolsHealthcare
38.4Bluescore
Momentum68.0
Market MapEarly Stage
Rank change (7d)▼ 20

Executive Summary

Updated Nov 1, 2026

What they do

  • Maintains the Healthcare Map, de-identified journeys for over 330 million patients
  • Sells the MapLab platform with no-code and natural-language tools for life sciences analytics
  • Offers Marmot, an AI engine for healthcare that turns questions into checkable analyses

Why it matters

  • Links claims, EHR, lab and provider data into one longitudinal patient view
  • Lets commercial, medical and real-world-evidence teams get insights without big analyst backlogs
  • Partners include Alnylam (now enterprise-wide), GeneDx, NCQA and Nasdaq

Best fit

  • Pharma and biotech commercial, market access and brand analytics teams
  • Real-world-evidence and HEOR groups needing large linked US patient datasets
  • Rare disease and specialty drug makers sizing patient populations and HCP targets

Watch-outs

  • Coverage is mainly US data, so global programs will need other sources
  • Headcount fell about 5% and no new funding round reported since 2022
  • Marmot AI launched only in 2025, so verify output accuracy and auditability

Products & Offerings

Healthcare Map

Komodo's core asset: de-identified, longitudinal US data on more than 330 million patient journeys, linking claims, EHR, lab and provider data.

DataEnterpriseCore Platform

Marmot

Komodo's AI engine built for healthcare, which turns plain-language questions into analyses on the Healthcare Map that users can check, with versions for commercial and other life sciences teams.

PlatformEnterpriseFlagship2025

MapLab

Komodo's enterprise analytics platform, a suite of apps and tools for querying the Healthcare Map, building patient cohorts and analyzing data.

EnterpriseEnterpriseLive

MapAI

An AI assistant built into MapLab that uses natural language processing so non-technical users can ask questions of the healthcare data in plain language.

PlatformEnterpriseLive2024

MapExplorer

A no-code MapLab tool for exploring patient populations, treatment patterns and provider data without writing queries.

EnterpriseEnterpriseLive2024

Latest News

Analyst VerdictShortlist

Updated Nov 1, 2026

Komodo Health is one of the main US sources of real-world patient data for life sciences, and its MapLab and Marmot AI layers make that data usable beyond specialist analysts. Pharma and biotech buyers of commercial or real-world-evidence analytics should include it alongside IQVIA and similar data providers. During evaluation, check how complete the data is for your therapy areas, how well the AI shows its work, and the full cost of licensing.

Signal Provenance

Latest observation date and source for each signal category

Signal CategoryLast UpdatedSource
Funding Signals
Last funding round, Funding stage
Nov 14, 2026Cited web research
Hiring Velocity
Headcount, Headcount growth
Nov 13, 2026Research agents (estimate)
Technical Output
Research papers, GitHub activity
Nov 15, 2026Hugging Face Hub + news feed + research agents
News Sentiment
News mentions, News sentiment
Nov 15, 2026Verified news feed
Partnership Signals
Enterprise partnerships, Distribution partners
Jun 5, 2026Research agents (estimate)
Revenue Indicators
ARR estimate, Revenue growth
Nov 15, 2026Research agents (estimate)
Leadership Signals
CEO tenure, Founder-led
Nov 15, 2026Research agents (estimate)
Competitive Position
Category rank, Market share
Nov 15, 2026Research agents (estimate)

Why this Bluescore?

6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology

Komodo Health's Bluescore of 38.4 rests most on Investment Momentum (6.1, 72nd percentile) and Business Model & Revenue (4.5, 61st percentile). Its weakest area is Talent & Research (2.0, 1st percentile).

In plain English

Komodo Health has a Bluescore of 38.4 and ranks #199 of 247 overall, down 4 places since yesterday. Its strongest contributions come from Investment Momentum, which scores 6.1 of 10 at the 72nd percentile, and Business Model & Revenue, which scores 4.5 of 10 at the 61st percentile, while Talent & Research (2.0 of 10, 1st percentile) and Customer Adoption (3.8 of 10, 4th percentile) hold it back most. The biggest lever is Product Depth, which carries a 21% weight and has 13.1 points still available, so moving its 3.8 of 10 score would add more to the Bluescore than any other dimension.

Written by AI from the scores below and checked against them; updated nightly.

D1 · Business Model & Revenue (21%)
4.5
+9.5 of 21 pts · 61st pct
D2 · Product Depth (21%)
3.8
+7.9 of 21 pts · 29th pct
D3 · Data & Model Moat (19%)
3.6
+6.8 of 19 pts · 43rd pct
D4 · Talent & Research (16%)
2.0
+3.2 of 16 pts · 1st pct
D5 · Customer Adoption (13%)
3.8
+5.0 of 13 pts · 4th pct
D6 · Investment Momentum (10%)
6.1
+6.1 of 10 pts · 72nd pct

Traction Signals

Last Round

Series F

Risks

Updated Nov 1, 2026

Heavy reliance on third-party claims and EHR feeds that could change or be lost
Medium
Re-identification and patient-privacy scrutiny of de-identified US health data keeps tightening
Medium
Late-stage private company with stalled IPO plans, past layoffs and slowly shrinking headcount
Medium
Generative AI answers on clinical data need validation before use in regulated decisions
Medium
Strong competition from IQVIA, Optum, Truveta and HealthVerity may limit Komodo's differentiation
Low
Feedback